Literature DB >> 1536979

Bone mineral density of the proximal femur and lumbar spine in glucocorticoid-treated asthmatic patients.

I R Reid1, M C Evans, D J Wattie, R Ames, T F Cundy.   

Abstract

The importance of the proximal femur as a site of osteoporotic fractures, the development of techniques for bone mineral density (BMD) measurement at this site and the apparent selectivity of the osteopenic effects of glucocorticoids have focused attention on the assessment of proximal femoral BMD in steroid-treated subjects. We have, therefore, measured BMD (Lunar DPX) in the lumbar spine and proximal femur of 31 asthmatic patients receiving long-term glucocorticoid therapy (mean +/- SEM dose 16 +/- 1 mg prednisone/day, mean duration 10 +/- 2 years). BMD values expressed as the percentage of normal age- and sex-appropriate mean values, after weight adjustment, were as follows: lumbar spine 80 +/- 2%, femoral neck 83 +/- 2%, Ward's triangle 78 +/- 3% and trochanter 86 +/- 2%. All these values were significantly less than control (p less than 0.0001) and the decrement in BMD was more marked in Ward's triangle than at the other two femoral sites (p less than 0.05). In all regions BMD was unrelated to dose or duration of steroid treatment. It is concluded that there are reductions in the BMD of the lumbar spine and proximal femur in glucocorticoid-treated asthmatics, probably reflecting the mixed cortical/trabecular make-up of both regions.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1536979     DOI: 10.1007/bf01623844

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  13 in total

1.  Determinants of vertebral mineral density in patients receiving long-term glucocorticoid therapy.

Authors:  I R Reid; S W Heap
Journal:  Arch Intern Med       Date:  1990-12

2.  Corticosteroid effects on proximal femur bone loss.

Authors:  P Sambrook; J Birmingham; S Kempler; P Kelly; S Eberl; N Pocock; M Yeates; J Eisman
Journal:  J Bone Miner Res       Date:  1990-12       Impact factor: 6.741

3.  The impact of osteophytic and vascular calcifications on vertebral mineral density measurements in men.

Authors:  E S Orwoll; S K Oviatt; T Mann
Journal:  J Clin Endocrinol Metab       Date:  1990-04       Impact factor: 5.958

4.  Bone mineral density in Australia compared with the United States.

Authors:  N A Pocock; J A Eisman; R B Mazess; P N Sambrook; M G Yeates; J Freund
Journal:  J Bone Miner Res       Date:  1988-12       Impact factor: 6.741

5.  Effect of chronic corticosteroid administration on diaphyseal and metaphyseal bone mass.

Authors:  T J Hahn; V C Boisseau; L V Avioli
Journal:  J Clin Endocrinol Metab       Date:  1974-08       Impact factor: 5.958

6.  Bone mineral content of the femoral neck and shaft: relation between cortical and trabecular bone.

Authors:  H Bohr; O Schaadt
Journal:  Calcif Tissue Int       Date:  1985-07       Impact factor: 4.333

7.  Bone mineral in lumbar spine, femoral neck and femoral shaft measured by dual photon absorptiometry with 153-gadolineum in prednisone treatment.

Authors:  O Schaadt; H Bohr
Journal:  Adv Exp Med Biol       Date:  1984       Impact factor: 2.622

8.  Steroid-induced fractures and bone loss in patients with asthma.

Authors:  A D Adinoff; J R Hollister
Journal:  N Engl J Med       Date:  1983-08-04       Impact factor: 91.245

9.  Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD).

Authors:  I R Reid; A R King; C J Alexander; H K Ibbertson
Journal:  Lancet       Date:  1988-01-23       Impact factor: 79.321

10.  The proportion of trabecular bone in human vertebrae.

Authors:  S Y Nottestad; J J Baumel; D B Kimmel; R R Recker; R P Heaney
Journal:  J Bone Miner Res       Date:  1987-06       Impact factor: 6.741

View more
  9 in total

1.  Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study.

Authors:  J Jahnsen; J A Falch; E Aadland; P Mowinckel
Journal:  Gut       Date:  1997-03       Impact factor: 23.059

2.  Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club.

Authors:  Jean-Pierre Devogelaer; Stefan Goemaere; Steven Boonen; Jean-Jacques Body; Jean-Marc Kaufman; Jean-Yves Reginster; Serge Rozenberg; Yves Boutsen
Journal:  Osteoporos Int       Date:  2005-10-11       Impact factor: 4.507

Review 3.  Steroid osteoporosis.

Authors:  I R Reid
Journal:  Osteoporos Int       Date:  1993       Impact factor: 4.507

4.  A randomized controlled trial of salmon calcitonin to prevent bone loss in corticosteroid-treated temporal arteritis and polymyalgia rheumatica.

Authors:  J H Healey; S A Paget; P Williams-Russo; T P Szatrowski; R Schneider; H Spiera; H Mitnick; K Ales; P Schwartzberg
Journal:  Calcif Tissue Int       Date:  1996-02       Impact factor: 4.333

Review 5.  Consensus of an international panel on the clinical utility of bone mass measurements in the detection of low bone mass in the adult population.

Authors:  P D Miller; S L Bonnick; C J Rosen
Journal:  Calcif Tissue Int       Date:  1996-04       Impact factor: 4.333

6.  Correlation of Bone Mineral Parameters with Anthropometric Measurements and the Effect of Glucocorticoids on Bone Mineral Parameters in Congenital Adrenal Hyperplasia.

Authors:  Ramaswamy Ganesh; Natarajan Suresh; Lalitha Janakiraman; Karnam Ravikumar
Journal:  Indian J Pediatr       Date:  2015-07-31       Impact factor: 1.967

7.  Inhaled and oral corticosteroids: their effects on bone mineral density in older adults.

Authors:  J F Marystone; E L Barrett-Connor; D J Morton
Journal:  Am J Public Health       Date:  1995-12       Impact factor: 9.308

8.  Effects of glucocorticoids on skeletal growth in rabbits evaluated by dual-photon absorptiometry, microscopic connectivity and vertebral compressive strength.

Authors:  B Grardel; B Sutter; B Flautre; E Viguier; F Lavaste; P Hardouin
Journal:  Osteoporos Int       Date:  1994-07       Impact factor: 4.507

9.  Curcumin alleviates glucocorticoid-induced osteoporosis through the regulation of the Wnt signaling pathway.

Authors:  Zhiguang Chen; Jinqi Xue; Tao Shen; Shuai Mu; Qin Fu
Journal:  Int J Mol Med       Date:  2015-12-11       Impact factor: 4.101

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.